1. Home
  2. LPRO vs CGEM Comparison

LPRO vs CGEM Comparison

Compare LPRO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Open Lending Corporation

LPRO

Open Lending Corporation

HOLD

Current Price

$1.62

Market Cap

252.9M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.15

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPRO
CGEM
Founded
2000
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.9M
671.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LPRO
CGEM
Price
$1.62
$10.15
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$2.83
$28.00
AVG Volume (30 Days)
513.2K
1.6M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,948,000.00
N/A
Revenue This Year
$306.66
N/A
Revenue Next Year
$7.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$5.68
52 Week High
$6.73
$13.33

Technical Indicators

Market Signals
Indicator
LPRO
CGEM
Relative Strength Index (RSI) 42.71 48.91
Support Level $1.58 $9.48
Resistance Level $1.87 $13.10
Average True Range (ATR) 0.10 0.92
MACD -0.01 -0.33
Stochastic Oscillator 14.52 17.40

Price Performance

Historical Comparison
LPRO
CGEM

About LPRO Open Lending Corporation

Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: